Update information
November 2016: Recommendation 1.3 has been amended in response to the publication of NICE's technology appraisal guidance on dapagliflozin in triple therapy for treating type 2 diabetes.
December 2015: Recommendation 1.1 and the related NICE guidance section have been amended in response to the publication of the updated NICE guideline on type 2 diabetes in adults.
ISBN: 978-1-4731-0194-4